Yuan Che
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yuan Che has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Jianjun Chen
Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, USA
5 shared publications - Lillian Sau
Department of Systems Biology and Center for RNA Biology and Therapeutics, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA
5 shared publications - Miao Sun
Division of Genomic Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles/Keck School of Medicine of USC, Los Angeles, CA 90027, USA
5 shared publications - Bin Zhang
Gehr Family Center for Leukemia Research, Hematology Malignancies and Stem Cell Transplantation Institute, City of Hope Medical Center, Duarte, USA
4 shared publications - Chao Shen
Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 91016, USA
4 shared publications - Chengwan Zhang
Department of Central Laboratory, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China
4 shared publications
Latest Publications
- Open Access
- 12 May 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (10) , 1328-1343
Targeting PRMT9 Overcomes Venetoclax Resistance in AML by Modulating Splicing and Inhibiting Translation
Arginine methylation catalyzed by protein arginine methyltransferases (PRMTs) is required for cancer cell proliferation, but whether PRMTs mediate resistance to therapy remains elusive. Here, we have performed loss-of-function screens in venetoclax-resistant (VEN-R) AML patient-derived xenograft (PDX) cells and found that PRMT9 plays a critical role in promoting VEN resistance. Specifically, VEN-R AML samples exhibited high levels of PRMT9, and PRMT9 inhibition re-sensitized the AML cells to VEN treatment. In preclinical resistant models, genetic ablation of PRMT9 synergized with VEN to eradicate AML cells. Consistently, pharmacologic inhibition of PRMT9 combined with VEN yielded similar effects in VEN-R AML mouse models. Mechanistically, PRMT9 ablation disrupted RNA splicing by inducing exon-skipping of mRNA encoding ALG13, an UDP-N-Acetylglucosaminyltransferase subunit, downregulating expression of a VEN-efflux transporter encoded by the adenosine triphosphate binding cassette subfamily C member 1 (ABCC1) gene. PRMT9 inhibition also suppressed protein synthesis, downregulating short-lived oncoproteins, such as MCL1. These findings establish a connection between PRMT9-mediated arginine methylation and poor VEN responsiveness, also demonstrate that targeting PRMT9 may represent a viable strategy to overcome VEN resistance.
- 12 May 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (10) , 1328-1343
Open AccessTargeting PRMT9 Overcomes Venetoclax Resistance in AML by Modulating Splicing and Inhibiting Translation
Arginine methylation catalyzed by protein arginine methyltransferases (PRMTs) is required for cancer cell proliferation, but whether PRMTs mediate resistance to therapy remains elusive. Here, we have performed loss-of-function screens in venetoclax-resistant (VEN-R) AML patient-derived xenograft (PDX) cells and found that PRMT9 plays a critical role in promoting VEN resistance. Specifically, VEN-R AML samples exhibited high levels of PRMT9, and PRMT9 inhibition re-sensitized the AML cells to VEN treatment. In preclinical resistant models, genetic ablation of PRMT9 synergized with VEN to eradicate AML cells. Consistently, pharmacologic inhibition of PRMT9 combined with VEN yielded similar effects in VEN-R AML mouse models. Mechanistically, PRMT9 ablation disrupted RNA splicing by inducing exon-skipping of mRNA encoding ALG13, an UDP-N-Acetylglucosaminyltransferase subunit, downregulating expression of a VEN-efflux transporter encoded by the adenosine triphosphate binding cassette subfamily C member 1 (ABCC1) gene. PRMT9 inhibition also suppressed protein synthesis, downregulating short-lived oncoproteins, such as MCL1. These findings establish a connection between PRMT9-mediated arginine methylation and poor VEN responsiveness, also demonstrate that targeting PRMT9 may represent a viable strategy to overcome VEN resistance.
- Open Access
- 1 May 2026
- Published by KEAI Publishing in Genes & Diseases
- Vol. 13 (3) , 101879
A novel truncating variant in PRDM16 causes severe familial cardiomyopathy with variable clinical presentations
- 1 May 2026
- Published by KEAI Publishing in Genes & Diseases
- Vol. 13 (3) , 101879
Open AccessA novel truncating variant in PRDM16 causes severe familial cardiomyopathy with variable clinical presentations
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S3 from ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Supplementary Table S1: Effects of ALKBH1 KD on f5C34 in mitochondrial tRNA-Met Supplementary Table S2: Genetic background of the AML patient samples. Supplementary Table S3: List of oligonucleotide sequences
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S3 from ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Supplementary Table S1: Effects of ALKBH1 KD on f5C34 in mitochondrial tRNA-Met Supplementary Table S2: Genetic background of the AML patient samples. Supplementary Table S3: List of oligonucleotide sequences
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Proteomics Data 1 from ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Quantitative proteomics after ALKBH1 knockdown in MOLM13 cells.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Proteomics Data 1 from ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Quantitative proteomics after ALKBH1 knockdown in MOLM13 cells.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S7 from ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Supplementary Figure S1. ALKBH1 is required for human AML cell survival/growth in vitro and human AML progression in vivo. Supplementary Figure S2. ALKBH1 is required for leukemic cell transformation, LSC/LIC self-renewal and AML maintenance. Supplementary Figure S3. ALKBH1 is dispensable for normal hematopoiesis. Supplementary Figure S4. ALKBH1 is required for mitochondrial functions in AML cells. Supplementary Figure S5. ALKBH1 specifically catalyzes the conversion of m5C/m5Cm to f5C in tRNAs and is crutial for protein translation in AML. Supplementary Figure S6. WDR43 is a direct target of ALKBH1 through tRNA f5C-mediaed codon biased translation and phenocopies the functions of ALKBH1 in AML. Supplementary Figure S7. Discovery of the ALKBH1/WDR43/BCL2 axis and the synergistic effect of targeting ALKBH1/WDR43/BCL2 axis together with venetoclax in treating AML.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S7 from ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Supplementary Figure S1. ALKBH1 is required for human AML cell survival/growth in vitro and human AML progression in vivo. Supplementary Figure S2. ALKBH1 is required for leukemic cell transformation, LSC/LIC self-renewal and AML maintenance. Supplementary Figure S3. ALKBH1 is dispensable for normal hematopoiesis. Supplementary Figure S4. ALKBH1 is required for mitochondrial functions in AML cells. Supplementary Figure S5. ALKBH1 specifically catalyzes the conversion of m5C/m5Cm to f5C in tRNAs and is crutial for protein translation in AML. Supplementary Figure S6. WDR43 is a direct target of ALKBH1 through tRNA f5C-mediaed codon biased translation and phenocopies the functions of ALKBH1 in AML. Supplementary Figure S7. Discovery of the ALKBH1/WDR43/BCL2 axis and the synergistic effect of targeting ALKBH1/WDR43/BCL2 axis together with venetoclax in treating AML.
- 4 August 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (11) , 2298-2325
ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Cancer cells utilize codon-biased translation to fuel tumorigenesis and drug resistance; however, underlying mechanisms remain poorly understood. In this study, we show that ALKBH1 is overexpressed in acute myeloid leukemia (AML) and essential for leukemia stem cell/leukemia-initiating cell self-renewal and AML development/maintenance but dispensable for normal hematopoiesis. ALKBH1 enhances mitochondrial assembly/function and oxidative phosphorylation, crucial for AML survival/proliferation and resistance to venetoclax, a potent BCL2 inhibitor and widely used first-line targeted therapy for AML in the clinic. Mechanistically, ALKBH1 catalyzes 5-formylcytosine at tRNA wobble positions, reprograming decoding and facilitating codon-biased translation, a mechanism we term “epitranslatomic Midas touch,” which in turn drives leukemogenesis and drug resistance by promoting the synthesis of key oncogenic proteins like WDR43. Targeting ALKBH1, particularly together with venetoclax, exhibited potent antileukemia efficacy in preclinical models with favorable safety profiles. Collectively, our findings elucidate ALKBH1’s pivotal role in codon-biased translation and tumorigenesis and propose a novel therapeutic strategy for cancer treatment. Significance: This study uncovers that ALKBH1-driven tRNA-decoding reprogramming and codon-biased translation, termed “epitranslatomic Midas touch,” is crucial for leukemogenesis, leukemia stem cell/leukemia-initiating cell self-renewal, mitochondria structure/function, and resistance to venetoclax. Targeting ALKBH1, especially in combination with venetoclax, offers a promising therapeutic strategy to combat drug resistance in AML and potentially other ALKBH1-overexpressing cancers.
- 4 August 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (11) , 2298-2325
ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Cancer cells utilize codon-biased translation to fuel tumorigenesis and drug resistance; however, underlying mechanisms remain poorly understood. In this study, we show that ALKBH1 is overexpressed in acute myeloid leukemia (AML) and essential for leukemia stem cell/leukemia-initiating cell self-renewal and AML development/maintenance but dispensable for normal hematopoiesis. ALKBH1 enhances mitochondrial assembly/function and oxidative phosphorylation, crucial for AML survival/proliferation and resistance to venetoclax, a potent BCL2 inhibitor and widely used first-line targeted therapy for AML in the clinic. Mechanistically, ALKBH1 catalyzes 5-formylcytosine at tRNA wobble positions, reprograming decoding and facilitating codon-biased translation, a mechanism we term “epitranslatomic Midas touch,” which in turn drives leukemogenesis and drug resistance by promoting the synthesis of key oncogenic proteins like WDR43. Targeting ALKBH1, particularly together with venetoclax, exhibited potent antileukemia efficacy in preclinical models with favorable safety profiles. Collectively, our findings elucidate ALKBH1’s pivotal role in codon-biased translation and tumorigenesis and propose a novel therapeutic strategy for cancer treatment. Significance: This study uncovers that ALKBH1-driven tRNA-decoding reprogramming and codon-biased translation, termed “epitranslatomic Midas touch,” is crucial for leukemogenesis, leukemia stem cell/leukemia-initiating cell self-renewal, mitochondria structure/function, and resistance to venetoclax. Targeting ALKBH1, especially in combination with venetoclax, offers a promising therapeutic strategy to combat drug resistance in AML and potentially other ALKBH1-overexpressing cancers.